SANOFI-AVENTIS (EPA:SAN) | Finanzwire

Basculer en Français

9478	Companies
185496	Keywords
117875	Articles
99351	Press releases

Home
Companies
SANOFI-AVENTIS

PRESS RELEASE

published on 12/11/2024 at 07:00, 11 months 25 days ago

Press Release: Two combination vaccine candidates for prevention of influenza and COVID-19 granted Fast Track designation in the US
Sanofi's two combination vaccine candidates targeting influenza and COVID-19 granted Fast Track designation in the US. Candidates combine licensed vaccines to assess safety and immunogenicity in older adults

COVID-19 Sanofi Influenza Combination Vaccine Fast Track Designation
BRIEF

published on 12/09/2024 at 20:11, 11 months 26 days ago

Sarclisa Combinations Show Promise in Multiple Myeloma Treatment

Clinical Study Multiple Myeloma Sarclisa MRD Negativity Treatment Efficacy
PRESS RELEASE

published on 12/09/2024 at 20:06, 11 months 26 days ago

Press Release: ASH: Sarclisa combinations demonstrated significant benefits in newly diagnosed multiple myeloma patients
New data presented at ASH demonstrates significant clinical benefit with Sarclisa-based combinations in newly diagnosed multiple myeloma patients, highlighting deep and durable responses and improved outcomes

Multiple Myeloma Sarclisa ASH MRD Negativity Clinical Benefit
BRIEF

published on 12/07/2024 at 17:35, 11 months 28 days ago

Rilzabrutinib: Promising Advances in the Treatment of IPT

Security Efficiency Phase III Rilzabrutinib TPI
PRESS RELEASE

published on 12/07/2024 at 17:30, 11 months 28 days ago

Press Release: ASH: rilzabrutinib demonstrated significant patient benefit in the first positive phase 3 study of a BTK inhibitor in ITP
Positive phase 3 study shows rilzabrutinib benefits in ITP patients. Results include platelet response, reduced bleeding, improved quality of life. Safety and efficacy highlighted

Phase 3 Study Rilzabrutinib ITP BTK Inhibitor Patient Benefit
BRIEF

published on 12/06/2024 at 07:35, 11 months 30 days ago

Sanofi Publishes Revised Financial Statements Excluding Opella

Financial Statements Biopharma Sanofi 2024 Results Opella
PRESS RELEASE

published on 12/06/2024 at 07:30, 11 months 30 days ago

Press Release: Availability of the revised financial statements for Sanofi excluding Opella
Sanofi releases revised financial statements excluding Opella. The adjustments classify Opella as discontinued operations, aligning with Sanofi's transition to a biopharma company. Q4 2024 results expected on Jan 30, 2025

Sanofi Discontinued Operations Opella Revised Financial Statements Biopharma Company
PRESS RELEASE

published on 10/25/2024 at 07:30, 1 year 1 month ago

Press Release: Sanofi Q3: 15.7% sales growth boosted by earlier-than-anticipated vaccine sales; 2024 business EPS guidance raised due to strong business performance
BRIEF

published on 10/24/2024 at 14:05, 1 year 1 month ago

Positive Phase 3 Data for Dupixent in Chronic Spontaneous Urticaria Released

Dupixent Chronic Spontaneous Urticaria Phase 3 Data ACAAI Presentation Treatment Innovation
PRESS RELEASE

published on 10/24/2024 at 14:00, 1 year 1 month ago

Press Release: Dupixent late-breaking positive phase 3 data in chronic spontaneous urticaria to be presented at ACAAI
Dupixent phase 3 data in chronic spontaneous urticaria presented at ACAAI shows reduced itch and hive activity, potential new treatment for CSU patients

Dupixent Chronic Spontaneous Urticaria ACAAI Phase 3 Data Targeted Treatment

Accesswire

Published on 12/05/2025 at 17:00, 18 minutes ago

Three Trillion-Dollar Frontiers, One Technology: How SMX Is Everywhere at Once
Published on 12/05/2025 at 16:00, 1 hour 18 minutes ago

SMX Didn't Change Its Story; The World Finally Connected the Dots
Published on 12/05/2025 at 15:45, 1 hour 33 minutes ago

Critical Elements Announces Closing of C$7.0 Million Bought Deal Life Private Placement
Published on 12/05/2025 at 15:35, 1 hour 43 minutes ago

XCF Global Moves to Double SAF Production with New Rise Reno Expansion
Published on 12/05/2025 at 15:25, 1 hour 53 minutes ago

Usha Resources Provides Corporate Updates

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 17:00, 18 minutes ago

EQS-Adhoc: The NAGA Group AG adjusts guidance for financial year 2025 following continued low volatility and weaker year-end performance
Published on 12/05/2025 at 16:25, 53 minutes ago

4YFN26 Awards: Meet the Top 20 startups building the future
Published on 12/05/2025 at 16:10, 1 hour 8 minutes ago

Reorganization of the Eckert & Ziegler Executive Board
Published on 12/05/2025 at 16:00, 1 hour 18 minutes ago

EQS-Adhoc: TIN INN Holding AG implements financing strategy
Published on 12/05/2025 at 16:00, 1 hour 18 minutes ago

EQS-Adhoc: Amundi Physical Metals plc: Release of the Half-Year Financial Report as of September 30, 2025

Les Echos

Published on 12/05/2025 at 15:10, 2 hours 7 minutes ago

Mersen: Number of shares and voting rights as of November 30, 2025
Published on 12/05/2025 at 08:45, 8 hours 33 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/04/2025 at 18:00, 23 hours 18 minutes ago

Information concerning the total number of voting rights and shares in the share capital as of November 28, 2025
Published on 12/04/2025 at 17:45, 23 hours 33 minutes ago

MONTHLY INFORMATION RELATING TO THE TOTAL NUMBER OF VOTING RIGHTS AND SHARES MAKING UP THE SHARE CAPITAL
Published on 12/04/2025 at 17:44, 23 hours 34 minutes ago

Net profit attributable to owners of the parent up by 63% to €122 million, driven by business resilience and the improvement in Elior's contribution

View all LES ECHOS COMFI WIRE